Bulk harvest release testing for adventitious viruses is an integral part of biosafety for manufacturing biopharma products. Finding a testing strategy that works for diverse biologics modalities ...

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company ™, and several distinguished researchers will be ...

FORT DETRICK, Md. – Researchers at the U.S. Army Medical Research Institute of Infectious Diseases are testing a promising new biological threat detection method in high-fidelity training scenarios, ...

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

The non-coding genome, once dismissed as "junk DNA", is now recognized as a fundamental regulator of gene expression and a key player in understanding complex diseases. Following the landmark ...

Because of tumor heterogeneity and sampling error, next-generation sequencing (NGS) of glioblastoma (GBM) tumors may provide an incomplete picture of the somatic mutational landscape. We hypothesized ...

A hot potato: Next-generation DNA sequencing (NGS) faces mounting scrutiny over its cyber vulnerabilities. While NGS has revolutionized fields ranging from cancer diagnostics to infectious disease ...